Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer

Abroad (travel likely)RecruitingPHASE1

Conditions

Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 · Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 · Head and Neck Carcinoma of Unknown Primary · Locally Advanced Head and Neck Squamous Cell Carcinoma · Locally Advanced Hypopharyngeal Squamous Cell Carcinoma · Locally Advanced Laryngeal Squamous Cell Carcinoma · Locally Advanced Nasal Cavity Squamous Cell Carcinoma · Locally Advanced Oral Cavity Squamous Cell Carcinoma · Locally Advanced Oropharyngeal Squamous Cell Carcinoma · Locally Advanced Paranasal Sinus Squamous Cell Carcinoma · Locally Advanced Sinonasal Squamous Cell Carcinoma · Maxillary Sinus Squamous Cell Carcinoma · Stage III Hypopharyngeal Carcinoma AJCC v8 · Stage III Laryngeal Cancer AJCC v8 · Stage III Lip and Oral Cavity Cancer AJCC v8 · Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8 · Stage III Sinonasal Cancer AJCC v8 · Stage IVA Hypopharyngeal Carcinoma AJCC v8 · Stage IVA Laryngeal Cancer AJCC v8 · Stage IVA Lip and Oral Cavity Cancer AJCC v8 · Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8 · Stage IVA Sinonasal Cancer AJCC v8 · Stage IVB Hypopharyngeal Carcinoma AJCC v8 · Stage IVB Laryngeal Cancer AJCC v8 · Stage IVB Lip and Oral Cavity Cancer AJCC v8 · Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8 · Stage IVB Sinonasal Cancer AJCC v8

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations
  • Moffitt Cancer Center, Tampa, Florida, United States

    Contact: Study coordinator (Site Public Contact) · ClinicalTrials@moffitt.org · 800-679-0775
    Contact: Principal Investigator (George Q. Yang)
  • Northwestern University, Chicago, Illinois, United States

    Contact: Study coordinator (Site Public Contact) · cancer@northwestern.edu · 312-695-1301
    Contact: Principal Investigator (Laila A. Gharzai)
  • University of Kansas Clinical Research Center, Fairway, Kansas, United States

    Contact: Study coordinator (Site Public Contact) · KUCC_Navigation@kumc.edu · 913-588-3671
    Contact: Principal Investigator (Christopher Lominska)
  • University of Kansas Cancer Center, Kansas City, Kansas, United States

    Contact: Study coordinator (Site Public Contact) · KUCC_Navigation@kumc.edu · 913-588-3671
    Contact: Principal Investigator (Christopher Lominska)
  • University of Kansas Hospital-Westwood Cancer Center, Westwood, Kansas, United States

    Contact: Study coordinator (Site Public Contact) · KUCC_Navigation@kumc.edu · 913-588-3671
    Contact: Principal Investigator (Christopher Lominska)
  • University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States

  • University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States

    Contact: Study coordinator (Site Public Contact) · 800-888-8823
    Contact: Principal Investigator (Ranee Mehra)
  • Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

    Contact: Study coordinator (Site Public Contact) · 732-235-7356
    Contact: Principal Investigator (Malcolm D. Mattes)
  • Rutgers New Jersey Medical School, Newark, New Jersey, United States

    Contact: Study coordinator (Site Public Contact) · 732-235-7356
    Contact: Principal Investigator (Malcolm D. Mattes)
  • Montefiore Medical Center-Einstein Campus, The Bronx, New York, United States

    Contact: Study coordinator (Site Public Contact) · eskwak@montefiore.org · 718-379-6866
    Contact: Principal Investigator (Rafi Kabarriti)
  • Montefiore Medical Center - Moses Campus, The Bronx, New York, United States

    Contact: Study coordinator (Site Public Contact) · eskwak@montefiore.org · 718-379-6866
    Contact: Principal Investigator (Rafi Kabarriti)
  • Carolinas Medical Center/Levine Cancer Institute, Charlotte, North Carolina, United States

  • Atrium Health Cabarrus/LCI-Concord, Concord, North Carolina, United States

  • University of Cincinnati Cancer Center-UC Medical Center, Cincinnati, Ohio, United States

    Contact: Study coordinator (Site Public Contact) · cancer@uchealth.com · 513-584-7698
    Contact: Principal Investigator (Jordan Kharofa)
  • University of Cincinnati Cancer Center-West Chester, West Chester, Ohio, United States

    Contact: Study coordinator (Site Public Contact) · cancer@uchealth.com · 513-584-7698
    Contact: Principal Investigator (Jordan Kharofa)
  • University of Virginia Cancer Center, Charlottesville, Virginia, United States

  • VCU Massey Comprehensive Cancer Center, Richmond, Virginia, United States

    Contact: Study coordinator (Site Public Contact) · CTOclinops@vcu.edu · 804-628-6430
    Contact: Principal Investigator (Erin R. Alesi)
  • University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada

Study leads
  • Malcolm D Mattes

    Principal Investigator

    University Health Network Princess Margaret Cancer Center LAO